Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress

被引：20

作者：

Gabrielli, B. G. ^{[1
]}

Johnstone, R. W. ^{[3
]}

Saunders, N. A. ^{[2
,4
]}

机构：

[1] Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Cell Cycle Grp, Woolloongabba, Qld 4102, Australia

[2] Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Epithelial Pathobiol Grp, Woolloongabba, Qld 4102, Australia

[3] Peter MacCallum Canc Inst, Trescowthick Res Labs, Canc Immunol Div, Gene Regulat Lab, Melbourne, Vic 3000, Australia

[4] Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld, Australia

来源：

CURRENT CANCER DRUG TARGETS | 2002年 / 2卷 / 04期

关键词：

D O I：

10.2174/1568009023333818

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apoptosis and differentiation. Importantly, the modulation of these activities is likely to be mediated by alterations in the acetylation status of both histone and non-histone targets. Identification of these targets, and the specific histone deacetylase enzymes that modulate them, is an important step in designing rational-based therapies for the treatment of cancer. In this review we discuss the state of progress in identifying the molecular pathways/events mediating the anticancer activity of histone deacetylase inhibitors.

引用

页码：337 / 353

页数：17

共 120 条

[81] Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate [J].